Skip to main content

Advertisement

SpringerLink
Log in

Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 08 March 2017

Abstract

Background

The ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (e′, E/e′ ratio) as estimated by tissue Doppler imaging is a noninvasive surrogate for the left ventricular diastolic function. Because diastolic dysfunction usually precedes systolic dysfunction in cardiovascular diseases, we investigated whether monitoring the E/e′ ratio can help to predict the risk of trastuzumab-induced cardiotoxicity.

Methods

E/e′ ratio on tissue Doppler imaging was retrospectively reviewed to assess its value for early detection of the left ventricular ejection fraction (LVEF) decline in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer who received trastuzumab with or without cytotoxic chemotherapy. Echocardiography was performed at baseline and every 3 months after treatment began.

Results

Among 129 patients, LVEF declined in 25 (19 %) during trastuzumab treatment; the decline was grade 2 in 23 patients and grade 3 in 2. Elevation of the E/e′ ratio to more than 15 was detected in 17 patients (13 %), 7 of whom (5.4 % of total) concurrently had LVEF decline. A weak negative correlation was observed between E/e′ elevation and the worst LVEF decline (P = 0.0077), which was confirmed by multiple regression analysis (P = 0.023). E/e′ ratio at baseline or 3 months after beginning trastuzumab treatment was not significantly associated with the subsequent LVEF decline.

Conclusion

Monitoring of the left ventricular diastolic function on the basis of the E/e′ ratio at baseline or 3 months after is unlikely to predict LVEF decline in patients who receive trastuzumab. However, there is a potential chronological relation between E/e′ elevation and LVEF decline, implying that the degree of E/e′ elevation could have a role as a surrogate marker for predicting the LVEF decline characteristic of trastuzumab-induced cardiotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60:2504–12.

    Article  CAS  PubMed  Google Scholar 

  2. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH. Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104:1293–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31:4222–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F, ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23(Suppl 7):vii155–66.

    Article  PubMed  Google Scholar 

  5. Geisberg CA, Lenihan DJ. Neuregulin in heart failure: reverse translation from cancer cardiotoxicity to new heart failure therapy. Herz. 2011;36:306–10.

    Article  CAS  PubMed  Google Scholar 

  6. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bonow RO, Bacharach SL, Green MV, Kent KM, Rosing DR, Lipson LC, Leon MB, Epstein SE. Impaired left ventricular diastolic filling in patients with coronary artery disease: assessment with radionuclide angiography. Circulation. 1981;64:315–23.

    Article  CAS  PubMed  Google Scholar 

  8. Inouye I, Massie B, Loge D, Topic N, Silverstein D, Simpson P, Tubau J. Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension. Am J Cardiol. 1984;53:120–6.

    Article  CAS  PubMed  Google Scholar 

  9. Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U, Weitmann K, Hoffmann W, Poller W, Schultheiss HP, Pauschinger M, Tschope C. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation. 2007;116(6):637–47.

    Article  PubMed  Google Scholar 

  10. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nolè F, Veglia F, Cipolla CM. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910–6.

    Article  CAS  PubMed  Google Scholar 

  11. Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Vuolteenaho O, Hartikainen J. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med. 2002;251:228–34.

    Article  CAS  PubMed  Google Scholar 

  12. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, Coudert B, Cottin Y, Fumoleau P, Brunotte F. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat. 2011;130(3):845–54.

    Article  CAS  PubMed  Google Scholar 

  13. Reuvekamp EJ, Bulten BF, Nieuwenhuis AA, Meekes MR, de Haan AF, Tol J, Maas AH, Elias-Smale SE, de Geus-Oei LF. Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). J Nucl Cardiol. 2015. doi:10.1007/s12350-015-0164-x

  14. Serrano JM, González I, Del Castillo S, Muñiz J, Morales LJ, Moreno F, Jiménez R, Cristóbal C, Graupner C, Talavera P, Curcio A, Martínez P, Guerra JA, Alonso JJ. Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: incidence and predictors. Oncologist. 2015;20(8):864–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Ms. Yuka Murasaki for her technical assistance. This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Training Program for Oncology Professionals).

Author information

Authors and Affiliations

  1. Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai, Showa, Nagoya, 466-8560, Japan

    Kazunori Honda, Ayako Mitsuma & Yuichi Ando

  2. Department of Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan

    Kyosuke Takeshita

  3. Division of Biostatistics, Clinical Research Center, Aichi Medical University, Nagakute, Japan

    Kenta Murotani

  4. Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Japan

    Hironori Hayashi, Nobuyuki Tsunoda & Toyone Kikumori

  5. Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Toyoaki Murohara

Authors
  1. Kazunori Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyosuke Takeshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenta Murotani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayako Mitsuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hironori Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nobuyuki Tsunoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toyone Kikumori
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toyoaki Murohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuichi Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazunori Honda.

Ethics declarations

Conflict of interest

Yuichi Ando received research funding and honoraria from Chugai Pharmaceutical Co., Ltd. The other authors have no conflicts of interest to declare.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Honda, K., Takeshita, K., Murotani, K. et al. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer. Breast Cancer 24, 312–318 (2017). https://doi.org/10.1007/s12282-016-0705-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-016-0705-4

Keywords

Search

Navigation